Randomized Controlled Trial of Renal Denervation for Resistant Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 254 participants.
Also called NCT02900729
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 254 participants
- Sponsor
- Shanghai WiseGain Medical Devices Co., Ltd.
- Registry
-
NCT02900729
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02900729. Randomized; no masking; primary purpose treatment. Start 2016-10 (registry gives no type); primary completion 2017-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Controlled Trial of Renal Denervation for Resistant Hypertension
- Condition
- Hypertension
- Intervention (Device)
- Radiofrequency ablation catheter
- Intervention (Drug)
- Amlodipine, losartan potassium and hydrochlorothiazide
- Lead sponsor
- Shanghai WiseGain Medical Devices Co., Ltd.
Record details
- Record id
cardio:ct-nct02900729- Content hash
9ab2895012b9a18c5154d3c3c2da0dd35eb50029c1c76292f612d81d4e3d7348